CDC Testing Pause Puts Clinical Labs at the Center of Public Health Response
With CDC testing paused, clinical labs are stepping up to sustain surveillance and protect timely disease detection.
A temporary pause in infectious disease testing at the Centers for Disease Control and Prevention (CDC) is raising concerns among public health experts, even as officials emphasize the move is part of routine quality assurance efforts.
The CDC has halted testing for several diseases—including rabies, poxviruses, certain parasites, and lymphocytic choriomeningitis—leaving state and local laboratories to seek alternative testing pathways in the interim. The pause is expected to last at least a few weeks, though some experts predict a longer timeline before full services resume.
CDC Testing Pause Raises Surveillance Concerns, Despite Routine Review Efforts
Testing conducted by the CDC plays a critical role in national disease surveillance, particularly for smaller or resource-limited public health labs that rely on federal support for complex or uncommon diagnostics. According to an article from CIDRAP News, without that capacity, experts warn, there could be delays in identifying outbreaks or tracking disease spread.
Despite broader instability in public health infrastructure, Scott Becker, MS, CEO of the Association of Public Health Laboratories (APHL), said the pause is not tied to those challenges. Instead, he described it to CIDRAP News as part of an ongoing effort to evaluate testing quality that began in 2024.
“They’ve been very transparent about this all along,” Becker said, noting that the CDC’s testing portfolio is “enormous” and requires periodic review. (Photo credit: APHL)
Still, some public health leaders are uneasy about the broader implications. Sarah Henn, MD, MPH, chief health officer at Whitman-Walker Health, emphasized to CIDRAP News the importance of federal coordination in disease response.
“Right now, it is not clear that this level of coordination is in place, and that uncertainty is concerning,” she said.
State and Commercial Labs Step In as Capacity Strains Highlight Need for Systemwide Resilience
In the meantime, larger state and commercial laboratories are stepping in to fill the gap. Facilities such as the Wadsworth Center report they have significant but limited capacity to absorb additional testing demand.
Further, CIDRAP News reported that public health officials are cautioning that even temporary disruptions could impact early disease detection. “A strong public health system has redundancy,” said Ewa King, PhD, chief program officer at APHL, noting that labs are accustomed to sharing resources across jurisdictions.
Federal officials say some paused tests will return in the coming weeks. “In the meantime, CDC stands ready to support our state and local partners to access the public health testing they need,” said Emily G. Hilliard, press secretary for the Department of Health and Human Services.
For clinical laboratory professionals, the CDC’s temporary testing pause is a reminder of the essential role labs play in sustaining a resilient public health system. As demand shifts to state, local, and commercial laboratories, the ability to maintain turnaround times, ensure quality, and coordinate across jurisdictions becomes even more critical. While redundancy within the laboratory network helps absorb short-term disruptions, the situation underscores the importance of continued investment in workforce capacity, infrastructure, and inter-laboratory collaboration, areas that many clinical labs currently struggle with. In an environment where early detection drives effective response, clinical labs remain at the center of protecting population health.
—Janette Wider
